HMNC Brain Health Raises EUR 14.3 million to Advance Precision Psychiatry Therapies
Round Comprised of New and Former Investors, Including Dr. Josef Ackermann, Wilhelm Beier, Toni Kroos, and Carsten Maschmeyer First of...
Healthcare
Belite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim Data
“Potential Early Intervention with an Oral Treatment for Stargardt Disease and Dry Age-Related Macular Degeneration” Thursday, October 27th at 11...
NEXGEL Develops New Hydrogel Patch to Treat Amblyopia
Patch Will Be Available to Ophthalmologists and Optometrists in 1H 2023 Global Amblyopia Market Expected to Reach Over $6 Billion...
Avicanna Files Complete Patent Specifications Relating to a Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy
Recent in-vivo studies conducted in partnership with the University of Toronto confirm Formulation Candidate’s anti-seizure properties allowing for formalization of...
Kymera Therapeutics to Report Third Quarter 2022 Results on November 3
Company also presenting at upcoming investor conferencesWATERTOWN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a...
The Joint Corp. to Host Conference Call on Thursday, November 3rd to Discuss Third Quarter 2022 Results
SCOTTSDALE, Ariz., Oct. 20, 2022 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care...
Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting
REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing...
Bright Peak Therapeutics to Present Innovative Best-in-Class and Multifunctional Regulatory T Cell (Treg) Enhancers at the 10th International Conference on Autoimmunity: Mechanisms and Novel Treatments
– First presentation of BPT264, the only Treg-targeting IL-2 for autoimmune disease that is both IL2Rα-enhanced and IL2Rβ-dead, displaying best-in-class...
Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular...
Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared...
Indegene acquires CultHealth, a full-service, healthcare marketing agency to elevate brand experience
PRINCETON, N.J. and NEW YORK and BENGALURU, India, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization...
MIMEDX to Host Third Quarter 2022 Operating and Financial Results Conference Call on November 2
MARIETTA, Ga., Oct. 19, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental...
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022
--- Presentations Reinforce Topline Safety and Efficacy Findings and Highlight Consistency between Clinical and Microbiological EndpointsWALTHAM, Mass., Oct. 19, 2022...
Second United States Patent Granted for Small Pharma’s Psychedelics Portfolio
Brings total to twelve granted patents across the Company’s full portfolio LONDON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Small Pharma...
Nephros Third Quarter 2022 Financial Results Conference Call
SOUTH ORANGE, NJ, Oct. 19, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (Nasdaq: NEPH), a leading water technology...
Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022
BEDMINSTER, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused...
Plus Therapeutics Presents Preliminary Safety and Feasibility Data from ReSPECT-LM Clinical Trial at the European Association of Nuclear Medicine Congress
ReSPECT-LM Phase 1 clinical trial selected as TOP Trials Oral Presentation Treatment was well tolerated without dose limiting toxicities and...
Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care
Expanded partnership covers biosimilar candidates in immunology and oncologyREYKJAVIK, Iceland and BOUCHERVILLE, Quebec, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Alvotech...
Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care
Expanded partnership covers biosimilar candidates in immunology and oncologyAlvotech (NASDAQ: ALVO), a global biotech company specializing in the development and...
Nicox Provides Third Quarter 2022 Financial and Business Highlights
Press Release Nicox Provides Third Quarter 2022 Financial and Business HighlightsTopline results of the NCX 470 Mont Blanc Phase 3...